A polyphosphoester conjugate of melphalan as antitumoral agent

被引:19
作者
Bogomilova, Anita [1 ]
Hoehn, Miriam [2 ]
Guenther, Michael [2 ]
Herrmann, Annika [2 ]
Troev, Kolio [1 ]
Wagner, Ernst [2 ]
Schreiner, Laura [2 ]
机构
[1] Univ Munich, Dept Pharm, Ctr Syst Based Drug Res, Munich, Germany
[2] Bulgarian Acad Sci, Inst Polymers, BU-1113 Sofia, Bulgaria
关键词
Polymer-drug conjugate; EPR effect; Polyphosphoesters; Chemotherapeutics; GENE DELIVERY; IN-VITRO; SOLID TUMORS; CANCER; POLYMER; DRUG; DOXORUBICIN; COPOLYMER; MICELLES; CELLS;
D O I
10.1016/j.ejps.2013.08.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The low molecular weight of many chemotherapeutics causes their untargeted distribution in the body and fast renal clearance, which leads to a loss of therapeutic activity and to unspecific toxic side effects. Therefore, there is a growing interest in conjugating anticancer drugs to water soluble polymers and thus, take advantage of the 'enhanced permeability and retention' (EPR) effect in tumors. In this study, water soluble polyphosphoesters were used as polymer carriers of melphalan hydrochloride (hydrochloride of p-bis(2-chloroethyl)amino-L-phenylalanine), which is a multifunctional alkylating agent. Melphalan was chemically immobilized by covalent bonding to poly(oxyethylene H-phosphonate) under Atherton-Todd reaction conditions. Novel polymer-melphalan complexes with ionic and hydrogen bonds were designed as controls, basing on two other biodegradable polyphosphoesters: poly(hydroxyoxyethylene phosphate) and poly(methyloxyethylene phosphate). The structure of the formed products was elucidated by H-1, C-13, P-31 NMR and FT-IR spectroscopy. The cytotoxic effect of the melphalan formulations was evaluated on different tumor cell lines. The novel polymer formulations showed a concentration dependent antitumoral activity, comparable to the effect of unmodified melphalan. The polymer-melphalan conjugate was also evaluated in vivo in the human hepatocellular carcinoma HuH7 xenograft mouse model. It improved the therapeutic efficacy of pure melphalan without causing side effects. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:410 / 419
页数:10
相关论文
共 49 条
  • [1] BENTRUDE WG, 1987, METHODS STEREOCHEMIC, V8, P365
  • [2] Dollery C, 1991, MELPHALAN THERAPEUTI
  • [3] Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer
    Duncan, R
    Vicent, MJ
    Greco, F
    Nicholson, RI
    [J]. ENDOCRINE-RELATED CANCER, 2005, 12 : S189 - S199
  • [4] The dawning era of polymer therapeutics
    Duncan, R
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (05) : 347 - 360
  • [5] POLYMER CONJUGATES - PHARMACOKINETIC CONSIDERATIONS FOR DESIGN AND DEVELOPMENT
    DUNCAN, R
    SPREAFICO, F
    [J]. CLINICAL PHARMACOKINETICS, 1994, 27 (04) : 290 - 306
  • [6] Duncan R., 2005, ENCY MOL CELL BIOL M
  • [7] Duncan R., 2005, POLYM DRUG DELIVERY
  • [8] Fang J, 2003, ADV EXP MED BIOL, V519, P29
  • [9] The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect
    Fang, Jun
    Nakamura, Hideaki
    Maeda, Hiroshi
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2011, 63 (03) : 136 - 151
  • [10] FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182